Keyword: Japan

Novartis has a leg up in its race against Merck KGaA to bring rival lung cancer drugs to the U.S. But in Japan, Merck just landed a victory.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Japan’s Kyowa Kirin says it is putting quality assurance and pharmacovigilance with a reorganization that has the divisions report to the CEO.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Daiichi Sankyo is pulling out of its Movantik co-marketing deal with AstraZeneca and cutting loose two Inspirion opioid painkillers.

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

Sanofi has been paring away jobs on both sides of the Atlantic for years. Now, it's offering voluntary early retirements to employees in Japan.

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.